Total Payments
$3,993
2024 Payments
$856.60
Companies
17
Transactions
112
Medicare Patients
2,453
Medicare Billing
$220,356
Payment Breakdown by Category
Food & Beverage$3,381 (84.7%)
Travel$610.27 (15.3%)
Education$2.50 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,381 | 108 | 84.7% |
| Travel and Lodging | $610.27 | 2 | 15.3% |
| Education | $2.50 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,012 | 67 | $0 (2024) |
| Medtronic USA, Inc. | $792.51 | 8 | $0 (2019) |
| Eisai Inc. | $440.49 | 5 | $0 (2024) |
| SK Life Science, Inc. | $400.43 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $249.31 | 2 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $246.32 | 2 | $0 (2021) |
| Mitsubishi Tanabe Pharma America, Inc. | $126.06 | 1 | $0 (2018) |
| Vanda Pharmaceuticals Inc. | $124.80 | 1 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $115.44 | 1 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $113.35 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $856.60 | 22 | Eisai Inc. ($197.85) |
| 2023 | $717.70 | 34 | ABBVIE INC. ($445.42) |
| 2022 | $462.86 | 23 | ABBVIE INC. ($343.70) |
| 2021 | $473.43 | 13 | Biohaven Pharmaceuticals, Inc. ($246.32) |
| 2020 | $386.07 | 5 | Eisai Inc. ($242.64) |
| 2019 | $810.82 | 9 | Medtronic USA, Inc. ($792.51) |
| 2018 | $269.41 | 5 | Mitsubishi Tanabe Pharma America, Inc. ($126.06) |
| 2017 | $16.46 | 1 | Teva Pharmaceuticals USA, Inc. ($16.46) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $7.01 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $124.80 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 09/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/17/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: NEUROSCIENCE | ||||||
| 06/21/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $7.66 | General |
| Category: NEUROSCIENCE | ||||||
| 04/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $44.86 | General |
| Category: Neurology | ||||||
| 04/14/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $30.92 | General |
| 04/04/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $126.63 | General |
| Category: Neuroscience | ||||||
| 03/28/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $115.44 | General |
| Category: Neuropsychiatry | ||||||
| 03/25/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: NEUROSCIENCE | ||||||
| 03/25/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $1.67 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 03/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $122.07 | General |
| Category: Neurology | ||||||
| 03/13/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $124.65 | General |
| Category: Neurology | ||||||
| 02/29/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 02/29/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.03 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 02/27/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: NEUROSCIENCE | ||||||
| 02/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $3.48 | General |
| Category: NEUROSCIENCE | ||||||
| 01/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.51 | General |
| Category: NEUROSCIENCE | ||||||
| 01/17/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $5.89 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/19/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2023 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 427 | 530 | $125,211 | $38,112 |
| 2022 | 13 | 535 | 634 | $125,137 | $45,708 |
| 2021 | 14 | 698 | 841 | $169,379 | $63,836 |
| 2020 | 16 | 793 | 965 | $198,493 | $72,699 |
Total Patients
2,453
Total Services
2,970
Medicare Billing
$220,356
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 150 | 214 | $40,823 | $14,482 | 35.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 48 | 48 | $15,245 | $4,671 | 30.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 41 | $12,300 | $4,077 | 33.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 55 | $8,800 | $3,376 | 38.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $8,900 | $2,502 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $6,177 | $1,963 | 31.8% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 36 | 57 | $8,949 | $1,887 | 21.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 39 | 39 | $14,235 | $1,644 | 11.6% |
| 95912 | Nerve conduction, 11-12 studies | Facility | 2023 | 13 | 13 | $4,927 | $1,565 | 31.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 15 | $3,450 | $1,385 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 14 | $1,406 | $560.20 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 171 | 227 | $30,455 | $15,209 | 49.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 41 | $18,245 | $5,874 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 47 | 47 | $9,130 | $4,111 | 45.0% |
| 95913 | Nerve conduction, 13 or more studies | Facility | 2022 | 24 | 24 | $10,368 | $3,543 | 34.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 57 | $9,120 | $3,091 | 33.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 26 | 27 | $8,100 | $2,812 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $4,275 | $2,587 | 60.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 44 | 68 | $7,752 | $2,311 | 29.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 42 | 44 | $16,060 | $1,951 | 12.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 16 | 16 | $2,960 | $1,423 | 48.1% |
| 95912 | Nerve conduction, 11-12 studies | Facility | 2022 | 12 | 12 | $4,392 | $1,266 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 30 | 30 | $2,850 | $1,208 | 42.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2022 | 17 | 22 | $1,430 | $322.61 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 154 | 216 | $27,998 | $15,825 | 56.5% |
About Dr. Vikas Kumar, MD
Dr. Vikas Kumar, MD is a Neurology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1194928440.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vikas Kumar, MD has received a total of $3,993 in payments from pharmaceutical and medical device companies, with $856.60 received in 2024. These payments were reported across 112 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($3,381).
As a Medicare-enrolled provider, Kumar has provided services to 2,453 Medicare beneficiaries, totaling 2,970 services with total Medicare billing of $220,356. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Saint Louis, MO
- Active Since 06/06/2007
- Last Updated 11/12/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1194928440
Products in Payments
- ACTIVA (Device) $779.11
- BOTOX (Biological) $557.48
- QULIPTA (Drug) $380.26
- NURTEC ODT (Drug) $321.83
- XCOPRI (Drug) $250.59
- ZEPOSIA (Drug) $249.31
- Fycompa (Drug) $242.64
- UBRELVY (Drug) $175.60
- Leqembi (Drug) $166.93
- Cenobamate (Drug) $126.18
- Radicava (Drug) $126.06
- PONVORY (Drug) $124.80
- INGREZZA (Drug) $115.44
- ADUHELM (Biological) $98.68
- APTIOM (Drug) $92.40
- NORTHERA (Drug) $38.75
- KYNMOBI (Drug) $20.95
- SD809-HD (Drug) $16.46
- AIMOVIG (Biological) $16.09
- AUSTEDO (Drug) $14.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Saint Louis
Barry Singer
Neurology — Payments: $2.7M
Neurology $2.7M
Dr. Mark Tullman, M.d, M.D
Neurology — Payments: $2.1M
Neurology $2.1M
Dr. Robert Naismith, Md, MD
Neurology — Payments: $774,163
Neurology $774,163
Dr. Barbara Green, Md, MD
Neurology — Payments: $597,464
Neurology $597,464
Dr. Arun Varadhachary, Md, MD
Neurology — Payments: $373,665
Neurology $373,665
Dr. Anne Cross, Md, MD
Neurology — Payments: $270,789
Neurology $270,789